Vanda Pharmaceuticals, Inc. (VNDA)
3.75
+0.16
(+4.46%)
USD |
NASDAQ |
Nov 06, 10:32
Vanda Pharmaceuticals Net Income (Quarterly) : -22.56M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -22.56M |
| June 30, 2026 | -62.51M |
| March 31, 2026 | -48.57M |
| December 31, 2025 | -141.19M |
| September 30, 2025 | -22.59M |
| June 30, 2025 | -27.21M |
| March 31, 2025 | -29.49M |
| December 31, 2024 | -4.912M |
| September 30, 2024 | -5.324M |
| June 30, 2024 | -4.518M |
| March 31, 2024 | -4.146M |
| December 31, 2023 | -2.40M |
| September 30, 2023 | 0.137M |
| June 30, 2023 | 1.52M |
| March 31, 2023 | 3.252M |
| December 31, 2022 | 6.861M |
| September 30, 2022 | 3.27M |
| June 30, 2022 | 2.574M |
| March 31, 2022 | -6.43M |
| December 31, 2021 | 7.078M |
| September 30, 2021 | 7.771M |
| June 30, 2021 | 9.653M |
| March 31, 2021 | 8.65M |
| December 31, 2020 | 8.19M |
| September 30, 2020 | 5.947M |
| Date | Value |
|---|---|
| June 30, 2020 | 8.714M |
| March 31, 2020 | 0.486M |
| December 31, 2019 | 4.216M |
| September 30, 2019 | 100.42M |
| June 30, 2019 | 11.53M |
| March 31, 2019 | -0.612M |
| December 31, 2018 | 10.36M |
| September 30, 2018 | 7.171M |
| June 30, 2018 | 4.611M |
| March 31, 2018 | 3.066M |
| December 31, 2017 | -1.838M |
| September 30, 2017 | -4.55M |
| June 30, 2017 | -1.534M |
| March 31, 2017 | -7.645M |
| December 31, 2016 | -0.604M |
| September 30, 2016 | -0.43M |
| June 30, 2016 | -4.618M |
| March 31, 2016 | -12.36M |
| December 31, 2015 | -14.80M |
| September 30, 2015 | -9.461M |
| June 30, 2015 | -5.386M |
| March 31, 2015 | -10.22M |
| December 31, 2014 | 69.72M |
| September 30, 2014 | -1.426M |
| June 30, 2014 | -21.58M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | -9.605M |
| Protagonist Therapeutics, Inc. | 162.85M |
| Sagimet Biosciences, Inc. | -13.95M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 69.82M |
| Total Expenses (Quarterly) | 92.38M |
| EPS Diluted (Quarterly) | -0.3731 |
| Enterprise Value | 98.56M |
| Gross Profit Margin (Quarterly) | 91.21% |
| Profit Margin (Quarterly) | -32.32% |
| Earnings Yield | -123.1% |
| Normalized Earnings Yield | -123.12 |